Prostate-specific Membrane Antigen PET in Prostate Cancer.

Courtney Lawhn-Heath Ali Salavati Spencer C Behr Steven P Rowe Jeremie Calais Wolfgang P Fendler Mattias Eiber Louise Emmett Michael S Hofman Thomas A Hope

Radiology

From the Department of Radiology and Biomedical Imaging (C.L.H., S.C.B., T.A.H.) and Helen Diller Family Comprehensive Cancer Center (S.C.B., T.A.H.), University of California San Francisco, 505 Parnassus Ave, M391, San Francisco, CA 94143; Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Md (A.S., S.P.R.); Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (J.C.); Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (W.P.F.); Department of Nuclear Medicine, Technical University of Munich, Munich, Germany (M.E.); Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia (L.E.); Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).

Published: May 2021

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are crucial for locating prostate cancer during initial staging and managing recurrences.
PSMA PET imaging outperforms traditional imaging methods in detection rates and significantly alters treatment plans in many cases.
This review aims to discuss the evolution and clinical significance of PSMA PET, compare it with other imaging agents, and showcase several key PSMA PET agents enhancing prostate cancer imaging.

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.

Download full-text PDF	Source
http://dx.doi.org/10.1148/radiol.2021202771	DOI Listing

Publication Analysis

Top Keywords

prostate cancer

psma pet

prostate-specific membrane

membrane antigen

pet

antigen pet

pet prostate

cancer prostate-specific

antigen psma-targeted

psma-targeted radiopharmaceuticals

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!